3 ms·

The heart problems are from short term use in combination with azithromycin. Here's some guidance from the American College of Cardiology: https://www.acc.org

by DanBC 7y ago

The heart problems are from short term use in combination with azithromycin. Here's some guidance from the American College of Cardiology: https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19 https://www.acc.org/latest-in-cardiology/articles/2020/03/27... • Safety considerations for inpatient and outpatient use of hydroxychloroquine-azithromycin in clinical practice are outlined below. Additional sources of expert guidance are also available here. • The intensity of QT and arrhythmia monitoring should be considered in the context of risk level, resource availability and quarantine considerations. • Hydroxychloroquine or chloroquine therapy should occur in the context of a clinical trial or registry, until sufficient evidence is available for use in clinical practice. • IRB-approved protocols should guide use of hydroxychloroquine or chloroquine for pandemic research; suggestions for researchers are outlined below. • Hydroxychloroquine or chloroquine use outside of a clinical trial should occur at the direction of an infectious disease or COVID-19 expert, with cardiology input regarding QT monitoring.

MockObject 7y ago
> at the direction of a...COVID-19 expert There aren't any of those.
- jacquesm 7y ago
  Au contraire, this thread is full of them.
s1artibartfast 7y ago
>The heart problems are from short term use in combination with azithromycin. Is this true? I keep hearing this but it is not supported by your source. It seems that it is the azithromycin that is of concern, and with a death rate of 47 per million. Is there any data suggesting this is worse when co-administered? >Chloroquine, and its more contemporary derivative hydroxychloroquine, have remained in clinical use for more than a half-century as an effective therapy for treatment of some malarias, lupus, and rheumatoid arthritis. Data show inhibition of iKr and resultant mild QT prolongation associated with both agents. Despite these suggestive findings, several hundred million courses of chloroquine have been used worldwide making it one of the most widely used drugs in history, without reports of arrhythmic death under World Health Organization surveillance.4 Nonetheless, the absence of an active drug safety surveillance system in most countries limits reassurance from these observations. Azithromycin, a frequently used macrolide antibiotics lacks strong pharmacodynamic evidence of iKr inhibition. Epidemiologic studies have estimated an excess of 47 cardiovascular deaths which are presumed arrhythmic per 1 million completed courses, although recent studies suggest this may be overestimated.6-7 There is limited data evaluating the safety of combination therapy, however in vivo studies have shown no synergistic arrhythmic effects of azithromycin with or without chloroquine.

by DanBC 7y ago

MockObject 7y ago

> at the direction of a...COVID-19 expert There aren't any of those.

jacquesm 7y ago
Au contraire, this thread is full of them.

s1artibartfast 7y ago

>The heart problems are from short term use in combination with azithromycin. Is this true? I keep hearing this but it is not supported by your source. It seems that it is the azithromycin that is of concern, and with a death rate of 47 per million. Is there any data suggesting this is worse when co-administered? >Chloroquine, and its more contemporary derivative hydroxychloroquine, have remained in clinical use for more than a half-century as an effective therapy for treatment of some malarias, lupus, and rheumatoid arthritis. Data show inhibition of iKr and resultant mild QT prolongation associated with both agents. Despite these suggestive findings, several hundred million courses of chloroquine have been used worldwide making it one of the most widely used drugs in history, without reports of arrhythmic death under World Health Organization surveillance.4 Nonetheless, the absence of an active drug safety surveillance system in most countries limits reassurance from these observations. Azithromycin, a frequently used macrolide antibiotics lacks strong pharmacodynamic evidence of iKr inhibition. Epidemiologic studies have estimated an excess of 47 cardiovascular deaths which are presumed arrhythmic per 1 million completed courses, although recent studies suggest this may be overestimated.6-7 There is limited data evaluating the safety of combination therapy, however in vivo studies have shown no synergistic arrhythmic effects of azithromycin with or without chloroquine.